Project Grant R01AA033057
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $671,854 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct neurocomputational and ecological assessments of the mutual influence between alcohol craving and decision-making. The research examines the bidirectional interactions between alcohol craving and maladaptive decision-making in heavy and binge drinkers, with the goal of developing computational models that account for the...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $713,580 on August 6, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct imaging research on sex differences in the cortical reward system of people with alcohol use disorder. The research examines dopamine neurotransmission in the mesocortical pathway—which regulates executive functions, reward sensitivity, stress response, and cognitive function—comparing men and women with alcohol use disorder....
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $576,197 on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop and test a digital pill system paired with smartphone-delivered cognitive behavioral therapy to measure and support acamprosate adherence in individuals with alcohol use disorder and alcohol-associated liver disease. Yale will develop a user-centered adherence intervention called ACAMPROSYNC that combines a digital pill system...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $752,580 on June 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct a five-year experimental medicine trial examining semaglutide dose effects on metabolic dysfunction, stress hormones, craving, and alcohol use outcomes in individuals with comorbid alcohol use disorder and obesity. The trial compares semaglutide at 1 milligram and 2 milligram doses against placebo over a 20-week treatment period and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of the Department of Health and Human Services National Institutes of Health, awarded Yale University $663,419 on August 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate liver sinusoidal endothelial cell (LSEC) inflammation in alcohol-associated liver disease. The research addresses mechanisms by which alcohol disrupts LSEC homeostasis through two converging pathways: IL6 trans-signaling mediated...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $578,234 on August 20, 2026, under the Alcohol Research Programs (CFDA 93.273) to establish a translational human laboratory model investigating alcohol's effects on pain in persons with co-occurring alcohol use disorder and chronic pain. The research uses a computer-controlled intravenous alcohol clamp to quantify alcohol's biphasic effects on pain perception—analgesia during the ascending phase and hyperalgesia...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $100,228 under the Alcohol Research Programs (CFDA 93.273) on October 27, 2026, to investigate the neurobiological mechanisms underlying the co-occurrence of alcohol use disorder and post-traumatic stress disorder. The project examines how stress exposure disrupts excitation-inhibition balance in the medial prefrontal cortex, driving increased alcohol consumption and heightened motivation for alcohol use. Using single...
- Federal Grant Award Summary Yale University received a $2.0 million Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 10, 2025, with completion scheduled for August 31, 2029. This research initiative delivers a comprehensive whole-genome sequencing (WGS) study examining alcohol use disorder (AUD) across multiple biobanks and ancestries. The project leverages large-scale WGS data, single-cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $880,688 on August 4, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct research imaging glucocorticoid function in women with childhood trauma and alcohol use disorder. The research uses positron emission tomography with a novel radiotracer called [18F]FMOZAT to investigate brain cortisol as a potential biomarker of stress dysregulation in women with childhood trauma and alcohol use disorder. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $182,183 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop artificial intelligence agents that generate personalized, multimedia cognitive behavioral therapy content for alcohol use disorder treatment, targeting English speakers and Spanish speakers. The project will create AI-generated CBT content delivered via smartphone to address high-risk drinking periods, such as weekends. The...
The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $1,649,143 on August 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct psychometric evaluation of the Yale Alcohol Craving Scale, a patient-reported outcome measure for assessing alcohol craving severity. Yale will develop and validate the YACS by administering an online survey to 1,500 adults recruited from online panels, community settings, and treatment programs to ensure representation across drinking risk levels, treatment status, and demographic characteristics. The work encompasses three primary aims: establishing a stable, confirmable latent factor structure for the YACS; evaluating measurement invariance across sex, race, drinking risk level, and polysubstance use status; and examining additional psychometric properties using cross-sectional data. The evaluation addresses a gap in current alcohol research, as existing self-report measures of craving fail to meet basic scientific standards for reliability and validity, limiting clinicians' and researchers' ability to obtain meaningful data on this important construct that drives heavy alcohol use and represents a critical treatment target. Performance occurs in New Haven, Connecticut. The project period runs through April 30, 2030. This is a Project Grant, the standard assistance type under the Alcohol Research Programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 8/10/26 |